2022 Nelson’s Pediatric Antimicrobial Therapy, 28th Edition

2022 Nelson’s Pediatric Antimicrobial Therapy, 28th Edition 2022 Original PDF

13 $

AUTHORS: John S. Bradley MD (Editor), John D. Nelson MD (Editor), Dr. Barnett Elizabeth MD (Consultant Editor), Joseph B. Cantey MD MD MPH (Consultant Editor)

Category:

2022 Nelson’s Pediatric Antimicrobial Therapy, 28th Edition 2022 Original PDF

Completely updated and revised, the 28th edition of this best-selling reference provides instant access to the latest recommendations for treatment of infectious diseases in children.

For each disease, the authors provide a commentary to help select the best of all antimicrobial choices. Drug descriptions cover all antimicrobial agents available today and include complete information about dosing regimens.

TOPICS INCLUDE

  • Antimicrobial Therapy by Clinical Syndromes
  • Antimicrobial Therapy for Neonates
  • Choosing Among
    • Antibiotics
    • Antifungal Agents
    • Antiviral Agents
    • Antiparasitic Agents
  • Oral Step-down Therapy for Serious Infections
  • Prevention of Symptomatic Infection
  • Approach to Antibiotic Allergies
  • Antibiotic Stewardship

New in the 28th Edition

  • Updated recommendations on acute hematogenous osteomyelitis, based on newly published guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America, including information on a decrease in the incidence of MRSA infections, allowing the recommendation of cefazolin, again, in empiric therapy for most pediatric bone infections
  • Updated recommendations on influenza treatment and prophylaxis, reflecting American Academy of Pediatrics guidance for 2021–2022
  • Ceftazidime/avibactam now preferred over fluoroquinolones for treatment of Klebsiella pneumoniae carbapenemase–producing enteric bacilli, if susceptible
  • Cefiderocol, a new iron-binding siderophore cephalosporin class, recently approved in adults for treatment of many drug-resistant pathogens, particularly Acinetobacter, Stenotrophomonas, and Pseudomonas; under study in children
  • New dosing for posaconazole suspension formulation
  • New approaches to mucormycosis
  • Added baloxavir for children 12+ years old

AUTHORS: John S. Bradley MD (Editor), John D. Nelson MD (Editor), Dr. Barnett Elizabeth MD (Consultant Editor), Joseph B. Cantey MD MD MPH (Consultant Editor)

PAGES: 336

YEAR: 2022

PUBLICATION: AAP

LANGUAGE: English

Related Products